NDAORALTABLET
Approved
Sep 2005
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
7/8 — Comprehensive
ANGELIQ (drospirenone and estradiol) by Bayer is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 2005.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANGELIQ is an oral combination hormone therapy tablet containing drospirenone and estradiol, approved by the FDA in 2005 for menopausal symptom management. It works as an estrogen receptor agonist to alleviate vasomotor symptoms and other menopause-related conditions. The product represents a small-molecule approach to hormone replacement therapy in women.
$0.427MPart D
Peak5.3 years to LOEPeak-stage product with stable Medicare claims volume; commercial teams focused on patient retention and managed care negotiations rather than growth expansion.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia
Started May 2017
1,570 enrolled
Menopause
Angeliq Regulatory Post Marketing Surveillance
Started Jun 2007
4,078 enrolled
Postmenopausal PeriodOsteoporosis, Postmenopausal
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
Started Jan 2007
92 enrolled
PostmenopauseHypertensionPre-Hypertension
Efficacy and Tolerability of Angeliq in Thai Women
Started Sep 2005
55 enrolled
Postmenopause
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
Started Apr 2004
750 enrolled
HypertensionPostmenopause
Worked on ANGELIQ at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.